Objectives: This study was conducted to evaluate significance of the human papillomavirus (HPV) genotype by HPV DNA chip test in early-stage cervical carcinoma.
Methods: Between June 2002 and December 2005, 246 consecutive patients with invasive cervical carcinoma of International Federation of Gynecology and Obstetrics (FIGO) stage IB1 to IIA were retrospectively reviewed. We employed an HPV DNA chip test to detect the type-specific sequence of HPV from cervical swabs taken from women with biopsy-proven neoplastic lesions of the cervix.
Results: The 5-year progression-free survival (PFS) was 78.5%. Of the 246 patients, HPV DNA was detected in 92.7% of the patients, among which 88.6% harbored single-type and 11.4% contained multiple-type infection. HPV-16 and HPV-18 were detected in 56.5% and 15.4% of the patients, respectively. On multivariate analysis, FIGO stage, HPV-18 positivity, and lymph node status were independent prognostic factors predictive for disease progression. The risk of recurrence was higher for HPV-18 positivity (hazards ratio = 2.06; 95% confidence interval, 1.13 to 3.77). The 5-year PFS rate for patients with HPV-18 negative was 81.7%, which was higher than a PFS of 60.5% for HPV 18 positive (P < 0.01).
Conclusions: The HPV-18 genotype is reliable prognostic factor of early-stage cervical carcinoma and HPV-18 infection may need warrant special attention with intense follow up.